Business & Finance
Business and Finance
Business and Finance
Wed, March 16, 2011 InVivo Therapeutics to Sponsor 2008 Beijing Paralympic Gold Medal Sailing Champion Maureen McKinnon-Tucker in Campaign for 2012
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it will sponsor Paralympic Gold Medalist Maureen McKinnon-Tuckera™s Paralympic Sailing Campaign in 2011 and 2012 through her organization Sail, Challenge, Inspire. During this time, McKinnon-Tucker and her teammates will be competing for the chance to defend their 2008 gold medal at the 2012 Paralympic Games in London.
"While InVivo works to address the challenges of SCI treatment, we are proud to support those with challenging disabilities. It is with great pleasure that we support Maureen and her teammates as they continue their inspiring journey to return to the 2012 Paralympic Games."
McKinnon-Tuckera™s 2012 campaign follows her gold medal victory alongside her late crewmate Nick Scandone in the 2008 Paralympic Games in Beijing, during which McKinnon-Tucker also became the first woman to represent the United States in sailing for the Paralympic Games and to win a gold medal in the sport.
aMore than being a great athlete, Maureen sets a shining example to all people of how hard work and determination can turn a challenge into a championship,a said Frank Reynolds, CEO of InVivo Therapeutics. aWhile InVivo works to address the challenges of SCI treatment, we are proud to support those with challenging disabilities. It is with great pleasure that we support Maureen and her teammates as they continue their inspiring journey to return to the 2012 Paralympic Games.a
"My teammates, Gerry and Andy and I are proud and thankful to be sponsored by InVivo Therapeutics. They are a like-minded company to our team's belief that disability should not stop innovation and excellence,a said Maureen McKinnon-Tucker. aFrank's passion for treating paralysis is unmatched by anyone I have ever met and I am personally very pleased to wear their logo while we compete to capture the US Team spot for the 2012 London Games."
McKinnon-Tucker has been featured in many media outlets including NBC Sports, a two-hour NBC Paralympics special with Bob Costas, Sports Illustrated, Sail Magazine, and the HallMark Channel, and has received several accolades including a Paul G. Hearne Award from the American Association of People with Disabilities.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston.
About Sail, Challenge, Inspire Inc.
Sail, Challenge, Inspire Inc. is a Massachusetts non-profit corporation that serves to encourage elite, Paralympic-level disabled sailing and to administer and promote participation of disabled persons in sailing related programs, events and activities in Massachusetts and adjacent waters.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companya™s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
